Vaccine Therapy in Treating Patients With Stage IV Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mannkind Corporation
ClinicalTrials.gov Identifier:
NCT00023647
First received: September 13, 2001
Last updated: July 9, 2012
Last verified: July 2012

September 13, 2001
July 9, 2012
July 2000
April 2002   (final data collection date for primary outcome measure)
Frequency of adverse events assessed by complete blood count, blood chemistry, polymerase chain reaction, physical examination and urinalysis [ Time Frame: Individual 96-hour infusion periods on days 0, 14, 28 and 42 and on day 56 ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00023647 on ClinicalTrials.gov Archive Site
  • Change in magnitude of antigen-specific cytotoxic t-lymphocyte in peripheral blood mononuclear cells [ Time Frame: Day 0 (pre-study), last day of individual 96-hour infusion periods (days 4, 17, 31 and 45) and on day 56 ] [ Designated as safety issue: No ]
  • Assessment of delayed-type hypersensitivity to intradermal injections 24 hours after injection [ Time Frame: Days 1, 29 and 57 ] [ Designated as safety issue: No ]
  • Change in size of target lesions by x-ray computed tomography before (day 0) and after (day 56)treatment [ Time Frame: Change from pre-study (day 0) to day 56 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Vaccine Therapy in Treating Patients With Stage IV Melanoma
A Phase I Dose-Ranging Safety Study Using Intranodal Delivery of a Plasmid DNA (Synchrotope TA2M) in Adult Stage IV Melanoma Patients

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given directly into a lymph node in treating patients who have stage IV melanoma.

OBJECTIVES: I. Determine the safety and tolerability of intranodal Synchrotope TA2M plasmid DNA vaccine in patients with stage IV melanoma. II. Determine the immune response of patients treated with this vaccine. III. Determine the clinical response of patients treated with this vaccine.

OUTLINE: This is dose-escalation, multicenter study. Patients receive Synchrotope TA2M plasmid DNA vaccine intranodally continuously over 96 hours beginning on days 0, 14, 28, and 42. Treatment continues for up to 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 8 patients receive escalating doses of Synchrotope TA2M plasmid DNA vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of 8 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: Approximately 16-24 patients will be accrued for this study within 12 months.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Melanoma (Skin)
Biological: Synchrotope TA2M
Cancer Vaccine, Immunotherapy
  • Experimental: Synchrotope TA2M, 800 micrograms
    Tyrosinase peptides, 800 micrograms
    Intervention: Biological: Synchrotope TA2M
  • Experimental: Synchrotope TA2M, 200 micrograms
    Tyrosinase peptides, 200 micrograms
    Intervention: Biological: Synchrotope TA2M
  • Experimental: Synchrotope TA2M, 400 micrograms
    Tyrosinase peptides, 400 micrograms
    Intervention: Biological: Synchrotope TA2M
Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003 Jul 1;98(1):144-54.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
26
November 2002
April 2002   (final data collection date for primary outcome measure)

INCLUSION CRITERIA - Patient must meet the following during the screening and baseline visits:

  1. The patients or their legally acceptable representative must give signed informed consent for participation in the study before any study procedure is performed.
  2. Patients must be 18 years of age or older at pre-study
  3. Patients must be ambulatory, ECOG performance status of 0 or 1 (Appendix II)
  4. Patients have histologically confirmed diagnosis of Stage IV melanoma according to AJCC/UICC modified system with an expected survival time of more than 3 months
  5. Patients must be positive for HLA-A2 (Patients tested positive within 5 years of pre-study screening do not need to be tested again for HLA-A2)
  6. Patients must agree to use an acceptable method of birth control

    1. intrauterine device
    2. oral hormonal contraception
    3. combination of spermicide and barrier method or
    4. abstinence
  7. Female patients of childbearing potential must have a confirmed negative urine pregnancy test on Day 0

EXCLUSION CRITERIA - Patients meeting any of the following criteria will NOT be eligible for the study:

  1. Patients who have hematological abnormalities as evidenced by:

    1. Neutrophils < 1,500/mm3
    2. Leukocytes < 3,000/mm3
    3. Platelets < 75,000/mm3
    4. Hemoglobin < 9.0 g/dL
  2. Patients who have hepatic disease as evidenced by:

    1. SGOT/SGPT (AST/ALT) > 2.5 x the upper limit of normal (ULN)
    2. alkaline phosphatase > 2.5 x ULN
    3. Bilirubin > 1.5 x ULN\
    4. positive for hepatitis B surface antigen
    5. positive for hepatitis C antibody
  3. Patients who have known or suspected renal impairment as evidenced by:

    1. serum creatinine > 1.5 x ULN, and/or
    2. serum urea > 2.6 x ULN
  4. Patients with a history of ocular melanoma
  5. Patients with brain metastases, unless completed resected
  6. Patients with a positive HIV antibody test
  7. Patients with medical, sociological, or psychological impediments that may compromise compliance with the protocol
  8. Patients who are nursing, pregnant or planning to become pregnant within 6 months of treatment completion
  9. Patients who are receiving chemo-, radio- or immunotherapy concurrently or within the preceding four weeks
  10. Patients who are taking drugs that affect immune function such as systemic corticosteroids or immunomodulatory drugs concurrently or within the preceding four weeks
  11. Patients who are receiving any investigational drug concurrently or within the preceding four weeks
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00023647
CDR0000068847, CTL-207-216, CTL-BB-IND-9146, LAC-USC-10M001, NCI-V01-1666
No
Mannkind Corporation
Mannkind Corporation
Not Provided
Study Chair: Barbara Hickingbottom, JD, MD Mannkind Corporation
Mannkind Corporation
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP